Cancer Institute and Hospital, Chinese Academy of Medical Sciences
474
168
195
57
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.1%
5 terminated/withdrawn out of 474 trials
91.9%
+5.4% vs industry average
11%
51 trials in Phase 3/4
5%
3 of 57 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (474)
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
Role: lead
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
Role: lead
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
Role: lead
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
Role: lead
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Role: collaborator
Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Role: lead
Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)
Role: lead
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
Role: lead
PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC
Role: lead
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
Role: lead
Study of Wenyang Tongbi Formula in the Treatment of Chemotherapy-Induced Polyneuropathy
Role: lead
Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）
Role: lead
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
Role: lead
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
Role: lead
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
Role: lead
Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma
Role: lead
The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma
Role: collaborator
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Role: collaborator
Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
Role: lead
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
Role: lead